EUROFINS CEREP-REGR (ALECR.PA) Fundamental Analysis & Valuation

EPA:ALECR • FR0013256518

Current stock price

15800 EUR
+400 (+2.6%)
Last:

This ALECR.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

5

1. ALECR.PA Profitability Analysis

1.1 Basic Checks

  • In the past year ALECR was profitable.
  • ALECR had positive earnings in each of the past 5 years.
  • ALECR had a negative operating cash flow in each of the past 5 years.
ALECR.PA Yearly Net Income VS EBIT VS OCF VS FCFALECR.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M 4M 6M 8M 10M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 9.27%, ALECR belongs to the top of the industry, outperforming 88.89% of the companies in the same industry.
  • ALECR has a better Return On Equity (10.76%) than 66.67% of its industry peers.
  • ALECR has a worse Return On Invested Capital (5.78%) than 61.11% of its industry peers.
  • ALECR had an Average Return On Invested Capital over the past 3 years of 8.68%. This is in line with the industry average of 7.18%.
Industry RankSector Rank
ROA 9.27%
ROE 10.76%
ROIC 5.78%
ROA(3y)11.46%
ROA(5y)12.59%
ROE(3y)14.01%
ROE(5y)15.92%
ROIC(3y)8.68%
ROIC(5y)10.52%
ALECR.PA Yearly ROA, ROE, ROICALECR.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15 20

1.3 Margins

  • ALECR has a Profit Margin of 17.10%. This is amongst the best in the industry. ALECR outperforms 83.33% of its industry peers.
  • ALECR's Profit Margin has improved in the last couple of years.
  • With a Operating Margin value of 12.90%, ALECR is not doing good in the industry: 61.11% of the companies in the same industry are doing better.
  • ALECR's Operating Margin has declined in the last couple of years.
  • The Gross Margin of ALECR (85.48%) is better than 100.00% of its industry peers.
  • ALECR's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 12.9%
PM (TTM) 17.1%
GM 85.48%
OM growth 3Y-22.97%
OM growth 5Y-3.98%
PM growth 3Y-9.24%
PM growth 5Y4.64%
GM growth 3Y-0.24%
GM growth 5Y12.91%
ALECR.PA Yearly Profit, Operating, Gross MarginsALECR.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. ALECR.PA Health Analysis

2.1 Basic Checks

  • ALECR has about the same amout of shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, ALECR has about the same amount of shares outstanding.
  • The debt/assets ratio for ALECR is higher compared to a year ago.
ALECR.PA Yearly Shares OutstandingALECR.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 1K 2K 3K 4K
ALECR.PA Yearly Total Debt VS Total AssetsALECR.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

  • ALECR has an Altman-Z score of 11.39. This indicates that ALECR is financially healthy and has little risk of bankruptcy at the moment.
  • ALECR has a Altman-Z score of 11.39. This is amongst the best in the industry. ALECR outperforms 100.00% of its industry peers.
  • A Debt/Equity ratio of 0.00 indicates that ALECR is not too dependend on debt financing.
  • With an excellent Debt to Equity ratio value of 0.00, ALECR belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 11.39
ROIC/WACCN/A
WACCN/A
ALECR.PA Yearly LT Debt VS Equity VS FCFALECR.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M

2.3 Liquidity

  • ALECR has a Current Ratio of 7.32. This indicates that ALECR is financially healthy and has no problem in meeting its short term obligations.
  • ALECR has a Current ratio of 7.32. This is amongst the best in the industry. ALECR outperforms 100.00% of its industry peers.
  • A Quick Ratio of 6.89 indicates that ALECR has no problem at all paying its short term obligations.
  • With an excellent Quick ratio value of 6.89, ALECR belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.32
Quick Ratio 6.89
ALECR.PA Yearly Current Assets VS Current LiabilitesALECR.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. ALECR.PA Growth Analysis

3.1 Past

  • ALECR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.19%, which is quite good.
  • Measured over the past years, ALECR shows a quite strong growth in Earnings Per Share. The EPS has been growing by 10.36% on average per year.
  • Looking at the last year, ALECR shows a decrease in Revenue. The Revenue has decreased by -8.20% in the last year.
  • Measured over the past years, ALECR shows a small growth in Revenue. The Revenue has been growing by 5.46% on average per year.
EPS 1Y (TTM)18.19%
EPS 3Y-10.09%
EPS 5Y10.36%
EPS Q2Q%-2.23%
Revenue 1Y (TTM)-8.2%
Revenue growth 3Y-0.94%
Revenue growth 5Y5.46%
Sales Q2Q%-8.69%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALECR.PA Yearly Revenue VS EstimatesALECR.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

Find the best growth stocksShow best growing peers

2

4. ALECR.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 11.13, the valuation of ALECR can be described as very reasonable.
  • ALECR's Price/Earnings ratio is rather cheap when compared to the industry. ALECR is cheaper than 94.44% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 26.54. ALECR is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 11.13
Fwd PE N/A
ALECR.PA Price Earnings VS Forward Price EarningsALECR.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALECR.PA Per share dataALECR.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2K 4K 6K

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)1.07
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ALECR.PA Dividend Analysis

5.1 Amount

  • No dividends for ALECR!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ALECR.PA Fundamentals: All Metrics, Ratios and Statistics

EUROFINS CEREP-REGR

EPA:ALECR (4/10/2026, 7:00:00 PM)

15800

+400 (+2.6%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Industry Strength10.81
Industry Growth92
Earnings (Last)N/A
Earnings (Next)N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap158.00M
Revenue(TTM)40.46M
Net Income(TTM)7.25M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 11.13
Fwd PE N/A
P/S 3.73
P/FCF N/A
P/OCF N/A
P/B 2.34
P/tB 2.42
EV/EBITDA N/A
EPS(TTM)1419.54
EY8.98%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS4241.55
BVpS6742.8
TBVpS6518.8
PEG (NY)N/A
PEG (5Y)1.07
Graham Number14675.2 (-7.12%)
Profitability
Industry RankSector Rank
ROA 9.27%
ROE 10.76%
ROCE 7.9%
ROIC 5.78%
ROICexc 5.78%
ROICexgc 5.98%
OM 12.9%
PM (TTM) 17.1%
GM 85.48%
FCFM N/A
ROA(3y)11.46%
ROA(5y)12.59%
ROE(3y)14.01%
ROE(5y)15.92%
ROIC(3y)8.68%
ROIC(5y)10.52%
ROICexc(3y)10.02%
ROICexc(5y)11.75%
ROICexgc(3y)10.47%
ROICexgc(5y)12.36%
ROCE(3y)11.82%
ROCE(5y)14.33%
ROICexgc growth 3Y-35.1%
ROICexgc growth 5Y-16.99%
ROICexc growth 3Y-34.75%
ROICexc growth 5Y-16.18%
OM growth 3Y-22.97%
OM growth 5Y-3.98%
PM growth 3Y-9.24%
PM growth 5Y4.64%
GM growth 3Y-0.24%
GM growth 5Y12.91%
F-ScoreN/A
Asset Turnover0.54
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.32
Quick Ratio 6.89
Altman-Z 11.39
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.19%
EPS 3Y-10.09%
EPS 5Y10.36%
EPS Q2Q%-2.23%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-8.2%
Revenue growth 3Y-0.94%
Revenue growth 5Y5.46%
Sales Q2Q%-8.69%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-33.62%
EBIT growth 3Y-23.69%
EBIT growth 5Y1.27%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

EUROFINS CEREP-REGR / ALECR.PA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of EUROFINS CEREP-REGR (ALECR.PA) stock?

ChartMill assigns a fundamental rating of 4 / 10 to ALECR.PA.


What is the valuation status of EUROFINS CEREP-REGR (ALECR.PA) stock?

ChartMill assigns a valuation rating of 2 / 10 to EUROFINS CEREP-REGR (ALECR.PA). This can be considered as Overvalued.


Can you provide the profitability details for EUROFINS CEREP-REGR?

EUROFINS CEREP-REGR (ALECR.PA) has a profitability rating of 5 / 10.


How financially healthy is EUROFINS CEREP-REGR?

The financial health rating of EUROFINS CEREP-REGR (ALECR.PA) is 6 / 10.